Facing Stage 3 Rectal Cancer at 26: A New Targeted Therapy Cleared the Disease in Just 4 Months

At twenty-six, Mrinali Dhembla was focused on planning her wedding and building a future with her fiance. Instead, a series of easily dismissed symptoms led to a devastating reality: an aggressive stage 3 rectal cancer diagnosis. Her unexpected battle highlights a troubling and growing trend of colorectal cancer striking adults under fifty. Faced with the prospect of life-altering surgeries, her medical journey took a sudden turn when doctors uncovered a hidden genetic clue. This discovery not only explained her severe illness but opened the door to a revolutionary medical alternative that would completely change her prognosis.

A Shocking Diagnosis and a Hidden Genetic Link

Mrinali Dhembla was 26 and newly engaged. Instead of planning her wedding, she received a terrifying diagnosis: aggressive stage 3 rectal cancer that had already spread to her spine.

Her story reflects a growing trend of colorectal cancer in adults under 50. Like many young people, Dhembla brushed off early warning signs, including chronic constipation, low-grade fevers, and rectal bleeding.

“When you’re in your 20s, you just think that a little disturbance in your bowels isn’t a big thing,” she said. “You can just live through it.”

Testing soon revealed another surprise. Dhembla has Lynch syndrome, an inherited condition caused by mutated genes that are supposed to repair DNA.

Dr. Nicholas Hornstein, a medical oncologist at the Northwell Health Cancer Institute, described how the condition works.

“Think of these genes like a spellcheck system for your DNA,” Dr. Hornstein explained. “When cells divide, small errors naturally occur, and these mismatch repair proteins are supposed to find and fix those errors.”

For people with Lynch syndrome, that natural spellcheck is broken. DNA errors build up over time, which can eventually lead to cancer.

Dhembla had no idea she carried this genetic risk and had not undergone any early screenings. However, discovering this missing piece of the puzzle is exactly what helped her medical team figure out the best way to treat her specific tumor.

A Targeted Alternative to Traditional Surgery

The standard treatment for stage 3 rectal cancer typically involves chemotherapy, radiation, and surgery. For Dhembla, surgery carried severe, life-altering risks. She faced the possibility of complex spinal operations with potential neurological damage, or losing her rectum and requiring a permanent colostomy bag.

Fortunately, her genetic profile offered another option. She received an invitation to try a dual-immunotherapy regimen consisting of two drugs called nivolumab and ipilimumab.

This specialized treatment is highly effective for tumors classified as “MSI-high.” As Dr. Hornstein noted, this classification means the tumor’s DNA repair machinery is broken, which is exactly what happens with Lynch syndrome. While only about 15 percent of all colorectal cancers are MSI-high, these specific tumors are incredibly vulnerable to immunotherapy.

The two medications work as a team to unleash the body’s natural defenses. One drug activates the immune response and multiplies cancer-fighting white blood cells. The other drug removes the invisible shield that cancer cells use to hide from the immune system. By working together, they break through the tumor’s barriers and empower the patient’s own body to attack the disease directly.

Incredible Results and a Manageable Routine

The results of the dual-immunotherapy were remarkably swift. After just three infusions over the course of four months, Dhembla’s scans and biopsies showed absolutely no evidence of disease.

Medical tests revealed that her circulating tumor DNA, which are the molecules that cancer cells release into the bloodstream, plummeted from 300 to zero. By July 2025, she was officially declared cancer-free.

“[Dhembla’s] immune system did what surgery, chemotherapy and radiation may not have been able to do,” Dr. Hornstein noted, calling her case a profound example of precision medicine that matches the right treatment to the right biology.

By choosing this targeted approach, she also avoided the life-altering consequences of traditional surgery. While immunotherapy is not without side effects, such as potential fatigue, inflammation of the lungs or GI tract, and thyroid dysfunction, they are often much easier to manage.

For her, the primary side effect has been hypothyroidism. She now takes a pill every morning to manage the condition, but it is seamlessly built into her daily routine and does not cause any everyday disruptions.

Life After Treatment and the Road to Recovery

Now cancer-free, Dhembla is adjusting to a new normal. She relocated from New Hampshire to New York to be closer to her medical team and is settling into city life. While she successfully avoided surgery, her doctors are taking no chances with her long-term health.

She now adheres to a strict surveillance schedule. Dr. Hornstein emphasized that the medical team is watching her very closely to ensure the disease does not return. Because she achieved a complete clinical response, they rely on a combination of tools to monitor her progress without putting her through an operation.

This careful observation involves regular visits with a team of experts, including an oncologist, an endocrinologist, a gastrointestinal specialist, and a colorectal surgeon. Her routine includes a rectal scoping every three months. She also recently had a colonoscopy and is not due for another one for two years.

As for her personal life, Dhembla continues to plan her wedding with her fiance, Chris. The couple originally intended to marry soon but decided to postpone the celebration. Dhembla expressed that it is best to let the illness become a distant memory before walking down the aisle. She acknowledged that while her experience with the disease was relatively short, it left a profound impact, requiring time for emotional and mental healing.

The Power of Early Screening and Knowing Your Body

Dhembla’s experience serves as a crucial reminder that cancer does not discriminate by age. With colorectal cancer rates rising among younger adults, paying attention to early warning signs is more important than ever. Symptoms like chronic constipation or rectal bleeding should never be ignored, regardless of how young or healthy a person might feel.

Understanding family medical history is equally vital. Because of the high risk associated with Lynch syndrome, medical experts have specific screening guidelines. Individuals who know they carry this genetic mutation should begin colonoscopy screenings between the ages of 20 and 25. Alternatively, they should start screening two to five years before the youngest age at which a family member was diagnosed, whichever comes first.

For those at an average risk without a known genetic predisposition, routine colorectal cancer screening should begin at age 45.

While groundbreaking treatments like dual immunotherapy are changing the landscape of cancer care, early detection remains the most powerful tool. Dhembla’s journey highlights the incredible advancements in precision medicine, but it also underscores a simple truth: listening to your body and staying proactive about health screenings can save a life.